Free · 13,587 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Ophthalmic Treatments and Evolving Management of Sjögren's Disease: An Overview

AI-generated summary

The authors present a narrative overview of Sjögren's disease eye management, covering newer diagnostic markers, scleral lenses, and emerging therapies. They report a shift from palliative lubrication toward mechanism-directed approaches, but note that dedicated Sjögren's-specific trials are still needed to validate these interventions.

Who or what was studied
Patients with Sjögren's disease and ocular surface involvement (narrative overview, no specific population size reported)
Limits stated in the abstract
The abstract describes a narrative overview of PubMed and Google Scholar searches, not a systematic review, and states that dedicated Sjögren's-specific trials remain essential to validate the emerging interventions.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Sjögren's disease (SjD) causes severe ocular surface desiccation, progressing from aqueous-deficient dry eye (ADDE) to vision-threatening corneal ulceration, stromal melting, and perforation. Recent consensus guidelines and therapeutic innovations have transformed ophthalmic diagnosis and management.

Methods

A comprehensive narrative overview of PubMed and Google Scholar (July 2016-July2026) was conducted to evaluate updates in SjD diagnostics, ocular surface mechanics, topical/biological pharmacotherapies, neurostimulation, and meibomian gland interventions.

Results

Diagnostic parameters have shifted towards non-invasive salivary metabolomics (lactate, alanine, malate), regulatory non-coding RNAs (H19 ICR hypomethylation), tear point-of-care MMP-9 testing, and salivary gland ultrasonography (SGUS). Large-diameter scleral lenses provide continuous corneal fluid shielding, though edge design and surface modification are required to mitigate midday fogging. Additionally, emerging therapeutics are shifting care from palliative lubrication to targeted secretomotor and biological reactivation, including cold thermosensory TRPM8 agonists (acoltremon 0.003%), water-free formulations (0.1% cyclosporine, perfluorohexyloctane), reactive aldehyde species (RASP) modulators (reproxalap), syndecan-1 receptor agonists (Lacripep), systemic B-cell depleting biotherapy (ianalumab), trigeminal neurostimulation, and combined intense pulsed light with meibomian gland expression (IPL + MGX).

Conclusions

Ophthalmic SjD management has evolved from palliative lubrication toward a stepwise, mechanism-directed paradigm integrating novel diagnostics, secretomotor stimulation, mechanical protection, and biologic disease modification; dedicated SjD-specific trials remain essential to validate these emerging interventions.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Dry eye. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies